Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Celfib-AI: A machine learning model to predict bone marrow fibrosis and cellularity from complete blood count – a multicenter model development and validation study in France

Marie Donzel, Syrine KHEDIMALLAH, Sabrina Barriere et al. Nov 03, 2025 pp. 3801-3801 10.1182/blood-2025-3801

Abstract Introduction Bone marrow biopsy is an essential component of the WHO diagnostic criteria for myeloproliferative neoplasms (MPNs). Ho...

The heme pathway: A possible metabolic target for the treatment of hematologic cancers

Daniel Dransfield, Sean Silverman, Michael Reitsma et al. Nov 03, 2025 pp. 6783-6783 10.1182/blood-2025-6783

Abstract Hematologic malignancies constitute a diverse group of diseases, each characterized by distinct pathophysiological features. These...

Dogs with acute leukemia have shared and unique genetic mutations compared to human acute leukemia

Robert Harris, Dorothee Bienzle, Kristina Meichner et al. Nov 03, 2025 pp. 3500-3500 10.1182/blood-2025-3500

Abstract Introduction: Acute leukemia represents a heterogeneous group of aggressive hematopoietic malignancies in humans, broadly encompass...

Outcomes following MRD relapse in AML patients monitored by droplet digital PCR

Bo Wan, Curtis Hughesman, Yasser Abou Mourad et al. Nov 03, 2025 pp. 1738-1738 10.1182/blood-2025-1738

Abstract Introduction: European Leukemia Network (ELN) guidelines recommend PCR-based measurable residual disease (MRD) monitoring for patie...

Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 study

Agnieszka Wierzbowska, Agnieszka Pluta, Anna Czyz et al. Nov 03, 2025 pp. 344-344 10.1182/blood-2025-344

Abstract BACKGROUND: Measurable residual disease (MRD) is an important biomarker in AML. Detectable MRD (MRD+) after 2 cycles of intensive c...

Characteristics and outcomes in Acute Myeloid Leukemia with Mecom rearrangement treated with hypomethylating agent plus venetoclax

Leora Boussi, Elizabeth Corley, Andriy Derkach et al. Nov 03, 2025 pp. 1616-1616 10.1182/blood-2025-1616

Abstract Background: Acute myeloid leukemia with MECOM rearrangement (MECOMr AML) represents 1-2% of AML and is associated with poor long-te...

Two decades of infectious mortality in Myelodysplastic Syndromes: An analysis from the CDC wonder database

Muhammad Waseem Tahir, Diljot Singh, Zubia Tahir et al. Nov 03, 2025 pp. 6414-6414 10.1182/blood-2025-6414

Abstract Background Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by ineffective hematopoiesis and periph...

PRC2-regulated glycolysis-to-oxphos metabolic switch coordinates the onset of terminal erythropoiesis

Zhiling Shi, Jiazhuo Li, Panpan Zhu et al. Nov 03, 2025 pp. 1109-1109 10.1182/blood-2025-1109

Abstract Erythropoiesis is a complex, tightly regulated process involving sequential changes in epigenetics, metabolism, and proliferation....

Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study

Alessandro Lucchesi, Nicola Cooper, Bruno Fattizzo et al. Nov 03, 2025 pp. 2881-2881 10.1182/blood-2025-2881

Abstract Introduction: Warm autoimmune hemolytic anemia (wAIHA) is a rare form of anemia caused by the destruction of red blood cells (RBC)...

Maintenance therapy discontinuation for patients diagnosed with multiple myeloma without high-risk features in minimal residual disease (MRD) negative remission: An interim analysis

Sam Holt, Mehwish Sajwar, Katie Liston et al. Nov 03, 2025 pp. 2261-2261 10.1182/blood-2025-2261

Abstract Background: Continuous maintenance therapy is a standard practice for many physicians treating multiple myeloma (MM). Lenalidomide...

A case for CD38 targeted therapy in multi-refractory immune thrombocytopenia

Shahzeem Bhayani, Joshua Siner, Morey Blinder et al. Nov 03, 2025 pp. 6602-6602 10.1182/blood-2025-6602

Abstract Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody-mediated platelet destruction and bleeding co...

Sustained efficacy of zanubrutinib (zanu) vs bendamustine + rituximab (BR) in treatment (tx)-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN SLL/CLL) and continued favorable survival in non-randomized patients (pts) with del(17p): 6-year follow-up in the phase 3 SEQUOIA study

Constantine Tam, Talha Munir, Tadeusz Robak et al. Nov 03, 2025 pp. 2129-2129 10.1182/blood-2025-2129

Abstract Introduction: The SEQUOIA study (NCT03336333) evaluated zanu, a next-generation Bruton tyrosine kinase (BTK) inhibitor, in TN CLL/S...

1,200+ U2AF1 mutations reveal distinct clinicobiological features of the S34/Q157 co-mutation subgroup

Yujiao Jia, Haoxu Wang, Bingqing Huang et al. Nov 03, 2025 pp. 3499-3499 10.1182/blood-2025-3499

Abstract Background: The U2AF1 spliceosome gene recurrently acquires S34 (predominantly S34F/Y) and Q157 (primarily Q157P/R) mutations in mye...

Influenza as a less commonly recognized cause of hemophagocytic lymphohistiocytosis: A systematic review of case reports and case series

Kavya Balusu, Ali Abdelhay, Peter Kouides Nov 03, 2025 pp. 1200-1200 10.1182/blood-2025-1200

Abstract Introduction Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening hyper-inflammatory condition that c...

Molecular genetics configuration of chronic myeloid leukemia

Vasile Musteata Nov 03, 2025 pp. 7304-7304 10.1182/blood-2025-7304

Abstract Background: Chronic myeloid leukemia (CML) represents roughly 20% of all leukemia cases in adults, being the most common chronic my...

P-selectin blockade effectively prevents trauma-induced microvascular obstruction

Reheman Adili, Maria Ronquillo, Nicole Roads et al. Nov 03, 2025 pp. 1320-1320 10.1182/blood-2025-1320

Abstract Background: Trauma is a leading cause of morbidity and mortality worldwide. Although many patients survive the initial blood loss,...

Molecular profiling of lupus b cells reveals expansion of somatic mutations in lymphoma-related pathways

Yumika Shiba, Pathum Kossinna, Loic Caloren et al. Nov 03, 2025 pp. 628-628 10.1182/blood-2025-628

Abstract Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by sustained immune activation, disrupted B cell t...

CD48 as an additional marker for measurable residual disease assessment in pediatric Acute Myeloid Leukemia.

Margarita Maurer-Granofszky, Elena Varotto, Dagmar Schinnerl et al. Nov 03, 2025 pp. 1741-1741 10.1182/blood-2025-1741

Abstract Background Multidimensional flow cytometry-based measurable residual disease (MFC-MRD) assessment is an essenti...

Real-world effectiveness of romiplostim N01 with or without TPO-RA for cancer therapy-induced thrombocytopenia in cancer patients

Lei Xing, Haifeng Shi, Rongcan Xu et al. Nov 03, 2025 pp. 6585-6585 10.1182/blood-2025-6585

Abstract Background: Cancer therapy-induced thrombocytopenia (CTIT) refers to thrombocytopenia occurring in cancer patients as a result of a...

Exacerbation of anemia from hereditary spherocytosis during pregnancy: Characterization of severity and use of medical interventions

Ayana Watkins, Katherine Economy, Arielle Langer Nov 03, 2025 pp. 2876-2876 10.1182/blood-2025-2876

Abstract Background: Hereditary spherocytosis (HS) is a congenital hemolysis that worsens during pregnancy. The extent and the timing of ane...

Danicopan add-on therapy demonstrates positive efficacy and safety outcomes in advanced age adults with paroxysmal nocturnal hemoglobinuria and clinically significant extravascular hemolysis: A sub-analysis of the phase 3 ALPHA trial

Austin Kulasekararaj, Morag Griffin, Robert Brodsky et al. Nov 03, 2025 pp. 949-949 10.1182/blood-2025-949

Abstract Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by intravascular hemolysis, thrombosis,...

Metabolomic and epigenetic signatures of hemin-induced stress in sickle cell erythroblasts

Caixia Xi, Betty Pace, Xingguo Zhu Nov 03, 2025 pp. 2924-2924 10.1182/blood-2025-2924

Abstract Introduction: Patients with sickle cell disease (SCD) endure systemic hypoxia and chronic hemolysis, resulting in excessive heme ex...

Automated subtype classification of acute leukemia from bone marrow smears using a cross-platform deep learning model

Guangqi Wang, Hualong Zhao, Enmin Song et al. Nov 03, 2025 pp. 6128-6128 10.1182/blood-2025-6128

Abstract Introduction: Accurate morphological classification of acute leukemia (AL) subtypes from bone marrow smears (BMSs) remains a corner...

Navigating hematology and medical oncology fellowship websites: A comprehensive review and implications for applicants

Farhan Israr, Rafi Aibani, Aamer Ahmad et al. Nov 03, 2025 pp. 2874-2874 10.1182/blood-2025-2874

Abstract Background: With over 1.9 million new cancer diagnoses annually and better cancer survival in the United States, the demand for Acc...

Modeling discordant cardiac and renal recovery trajectories in AL amyloidosis using interpretable machine learning

John Hanna, Ran Zhao, Diana Basali et al. Nov 03, 2025 pp. 5743-5743 10.1182/blood-2025-5743

Abstract Background In systemic light chain (AL) amyloidosis, hematologic remission does not guarantee organ recovery. Discordance between h...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page